Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
256 hedge funds and large institutions have $2.88B invested in Sage Therapeutics in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 101 increasing their positions, 73 reducing their positions, and 46 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 73
2% less funds holding
Funds holding: 262 → 256 (-6)
4.31% less ownership
Funds ownership: 90.94% → 86.62% (-4.3%)
11% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 46
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
28% less capital invested
Capital invested by funds: $3.97B → $2.88B (-$1.1B)
53% less call options, than puts
Call options by funds: $58.6M | Put options by funds: $125M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$45.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.5M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$39.1M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$26.2M |
| 5 |
AG
Artal Group
Luxembourg
|
+$24.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$134M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$65.9M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$61M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$59M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$48.2M |
SAGE Hedge Fund Activity: Q2 2021 in Review
256 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2021, worth a combined $2.88B — down 28% from $3.97B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of SAGE and 41 opened new positions — a net loss of 5 holders — while 73 trimmed existing stakes and 101 added.
The largest buyer was Wellington Management Group, adding an estimated $45.7M. The largest seller was Fidelity Investments, cutting an estimated $134M.
- 256 institutional investors held Sage Therapeutics (SAGE) as of Q2 2021, down from 262 in Q1 2021.
- Funds reported $2.88B of Sage Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
- 41 funds opened new Sage Therapeutics positions in Q2 2021 and 46 closed out, a net change of -5 holders.
- The largest Sage Therapeutics buyer in Q2 2021 was Wellington Management Group, an estimated $45.7M added.
- The largest Sage Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $134M sold.
Based on aggregated 13F filings for Q2 2021.